Stockscreener 앱 받기
8.66
3.76%
-0.26
시간 외 거래:
8.33
-0.33
-3.81%
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update - MarketScreener
Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA - Nasdaq
Phathom Pharmaceuticals Announces FDA Correction to Orange Book - GuruFocus
Phathom Pharmaceuticals (PHAT) Secures Extended Exclusivity for VOQUEZNA | PHAT Stock News - GuruFocus
FDA extends Phathom’s VOQUEZNA exclusivity period to 2032 By Investing.com - Investing.com Canada
FDA Grants 10-Year Exclusivity for Breakthrough GERD Drug VOQUEZNA: Major Win for Phathom - Stock Titan
Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade - MSN
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy (PHAT) - Seeking Alpha
Phathom Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Phathom Pharmaceuticals (PHAT) Price Target Increased Following FDA Ruling | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Receives Buy Rating from HC Wainw - GuruFocus
Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals (PHAT) Analyst Rating Update: Price Target Raised to $17.00 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald - MSN
Phathom Pharmaceuticals (PHAT) Soars on FDA Approval and Market Exclusivity | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update - GuruFocus
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT - GuruFocus
FDA Grants Phathom Pharmaceuticals (PHAT) Extended Exclusivity f - GuruFocus
Phathom Pharmaceuticals (PHAT) Surges 90% After FDA Grants 10-Year Exclusivity for Voquezna - Wealth Daily
Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity - TipRanks
Phathom Pharmaceuticals (PHAT) Receives Continued Buy Rating fro - GuruFocus
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna - Benzinga
Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna - TipRanks
Needham sees FDA’s positive CP ruling as best-case outcome for Phathom - TipRanks
Phathom Pharmaceuticals Rides High On FDA's Drug Approval - Finimize
Phathom Soars 95% on FDA Exclusivity for VOQUEZNA - Wall Street Pit
Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity - Investing.com
Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity By Investing.com - Investing.com UK
PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT S - GuruFocus
Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada
Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock - Investing.com
PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT Stock News - GuruFocus
Stifel expects Phathom to ‘largely recover ground lost’ after FDA grants claim - TipRanks
PHAT Stock: Phathom Pharmaceuticals Stock Surges 128% as FDA Grants 10-Year Exclusivity for Voquezna - gondwanauniversity.org
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Says FDA Approves Co's Petition For 10 Years Exclusivity For Voquezna - MarketScreener
Phathom Pharmaceuticals (PHAT) Soars 125% on FDA Decision - GuruFocus
Phathom Pharmaceuticals Announces Positive FDA Decision to Recog - GuruFocus
Phathom Pharmaceuticals Shares Surge After FDA Grants 10-Year Exclusivity for Acid-Reducing Drug - marketscreener.com
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 | PHAT Stock News - GuruFocus
Phathom says FDA to correct Orange Book for Voquenza exclusivity - TipRanks
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory ... - Bluefield Daily Telegraph
Phathom Pharmaceuticals Announces Positive FDA Decision to - GlobeNewswire
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for Vquezna®? Tablets Through May 3, 2032 - MarketScreener
Phathom Pharmaceuticals shares soar on FDA exclusivity grant By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals shares soar on FDA exclusivity grant - Investing.com Australia
0.91%
2.21%
자본화:
|
볼륨(24시간):